Intellectus Partners LLC Sells 1,708 Shares of Illumina, Inc. (NASDAQ:ILMN)

Intellectus Partners LLC lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,198 shares of the life sciences company’s stock after selling 1,708 shares during the quarter. Intellectus Partners LLC’s holdings in Illumina were worth $2,255,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ILMN. Vanguard Group Inc. increased its stake in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after acquiring an additional 2,336,935 shares during the period. Barclays PLC boosted its position in Illumina by 120.0% in the third quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after buying an additional 964,709 shares in the last quarter. abrdn plc boosted its position in Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after buying an additional 299,827 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Illumina by 245.7% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock valued at $57,366,000 after buying an additional 296,990 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Illumina by 6.6% in the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after buying an additional 225,074 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN traded up $1.23 during trading hours on Friday, hitting $122.28. The stock had a trading volume of 829,331 shares, compared to its average volume of 1,470,247. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.91. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $131.51 and its 200-day moving average is $127.31.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the firm earned $0.14 earnings per share. The business’s quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts forecast that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of the stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ILMN shares. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Barclays boosted their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research report on Thursday, January 4th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.